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The prothrombotic state in patients with cancer is a
major cause of morbidity which increases with the
approach of terminal illness. The occurrence of a
variety of arterial and venous thromboembolic dis-
orders in the presence of malignancy is called
Trousseau's syndrome.1 Migratory thrombophlebitis
and other symptoms of Trousseau's syndrome often
predate the diagnosis of neoplasia and should alert
physicians, especially in patients without risk factors
for thromboembolic complications. We discuss the
case of a patient with adenocarcinoma of the lung
who developed peripheral vascular disease and ulti-
mately died of thromboembolic complications.
Case Report
A 45-year-old woman was referred to the department
of Dermatology with migratory thrombophlebitis.
Three months later, an enlarged cervical lymph node
was detected. An anaplastic adenocarcinoma of the
lung was diagnosed and subsequently treated with
Carboplatin and Gemzar. The woman was discharged
home under oral anticoagulant therapy with Warfarin.
One year later she began to complain of exercise
induced pain in her lower limbs. The symptoms
rapidly progressed and the patient was admitted to
hospital complaining of rest pain in the right leg. APlease address all correspondence to: A. Assadian, email:
afshin_assadian@yahoo.de
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showed thromboembolic occlusion of both popliteal
arteries (Fig. 1). A thrombembolectomy of the right
superficial femoral and popliteal artery was performed.
Postoperatively, the Warfarin was stopped and intra-
venous unfractionated Heparin was commenced.
Three days later the patient had another acute epi-
sode of critical ischemia of the right leg along with a
sudden marked thrombocytopenia. Tests for Heparin
Induced Thrombocytopenia II (HIT II) were per-
formed, which were negative. Thrombocyte function
tests (Heparin induced platelet activation test ± HIPA ±
and Serotonin release test) as well as enhanced clot-
ting studies were performed, all showing levels of
activation of the coagulation system according to the
anticoagulation status. Again, an embolectomy was
performed yielding a white, flexible clot, outlining
the shape of the superficial femoral and popliteal
artery (Fig. 2). Histopathology showed it to consist
only of fibrin and thrombocytes.
Three days later, the patient developed further
critical ischaemia of the right and left leg. After re-
embolectomy, the left lower limb recovered but a
below knee amputation of the right leg became
inevitable 10 days after the first surgical procedure.
The patient died 6 weeks after she had been trans-
ferred to our department. The post mortem revealed a
metastasizing bronchial adenocarcinoma apT1 aN1
aM1, an abacterial endocarditis of the mitral valve
with multiple renal, splenic and myocardial infarc-
tions as well as a recent cerebral stroke in the middle
cerebral artery territory of the left hemisphere.icense.
Fig. 1. Digital subtraction angiography showing a thromboembolic
occlusion of both popliteal arteries.
Fig. 2. Specimen yielded at the second embolectomy. On top a 4 F
Fogarty Catheter.
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The clinical manifestations of cancer-related coagulo-
pathies include spontaneous migratory or recurrent
thrombophlebitis, arterial thrombosis, marantic endo-
carditis or accelerated peripheral vascular disease.
In cases of arterial thromboembolism aggressive
revascularisation attempts are appropriate. However,
the prognosis for limb salvage and long term survival
is not very promising. The choice of anticoagulant
therapy has a major role in preventing the incidence
of further complications from a procoagulant state.
Oral anticoagulation with Warfarin appears to be a
simple solution. However, only 19% of those treated
with Warfarin were unaffected by recurrent thrombo-
phlebitis or arterial embolism.1
Unfractionated Heparin (UFH) has a much more
prominent role in the long term treatment ofTrousseau's syndrome.2 Adequate therapy of the
underlying disease is imperative in the case of
patients with procoagulant states due to neoplasia.
As long as tumour cells persist, thromboses are likely.
It has been shown that some necrotic tumour cells do
have a high binding affinity for UFH. Heparin binding
by dead cells causes a significant reduction in the
anticoagulant activity of UFH.3
This effect occurs to a much lesser extent with Low
Molecular Weight Heparin (LMWH).3,4 LMWH is
also better absorbed after subcutaneous injection and
binds less to plasma, matrix proteins, thrombocytes
and macrophages. Due to the linear dose response
curve monitoring is not normally necessary.
A new promising substance is Fondaparinux, a syn-
thetic pentasaccharide causing selective inhibition of
activated factor X. In a recent study, one subcutaneous
injection of Fondaparinux daily yielded a comparative
risk reduction of venous thromboembolism of 56.4
compared to LMWH after surgery.5 Further studies
will have to clarify its role in the long term therapy
of procoagulant states.
References
1 Sack GH, Levin J, Bell W. Trousseau's syndrome and other
manifestations of chronic disseminated coagulopathy in patients
with neoplasms: clinical, pathologic, and therapeutic features.
Medicine 1977; 56: 1±37.EJVES Extra, 2002
96 A. Assadian et al.2 Bell WR, Starksen NF, Tong S, Porterfield JK. Trousseau's
syndrome. Devastating coagulopathy in the absence of heparin.
Am J Med 1985; 79: 423±430.
3 Morita S, Gebska MA, Kakkar AK, Scully MF. High
affinity binding of heparin by necrotic tumor cells
neutralise anticoagulant activity. Thromb Hemost 2001; 86:
616±622.EJVES Extra, 20024 Walsh-McMonagle D, Green D. Low molecular-weight
heparin in the management of Trousseau's syndrome. Cancer
1997; 80: 649±655.
5 Eriksson BI, Bauer KA, Lassen MR, Turpie AGG. Fonda-
parinux compared with Enoxaparin for the prevention of venous
thromboembolism after hip-fracture surgery. N Eng J Med 2001;
345: 1298±1304.
